drugset / Press release
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
2022-09-20 · Ono Pharmaceutical Co., Ltd. · original ono-pharma.com ↗
This material is intended to notify the press release issued on September 16 (local time) by Bristol Myers Squibb, our license partner for Opdivo. Please click https://www.bms.com/media/press-releases.html for the original press release.
The release as fetched from its publisher. ono-pharma.com ↗